Debt is cheap, markets are high and bankers are expecting more big M&A to close out the year.
Pharmaceutical firms rely on acquisitions to plug the gap on innovations they do not currently possess, says Albert Fried and Company's Sachin Shah.
Pfizer investors should be concerned about the high premium, while Medivation investors should celebrate, says RBC Capital Markets' Simos Simeonidis.
Jim Cramer looked ahead to Fed Chair Janet Yellen’s speech in Jackson Hole.
Jim Cramer isn't salivating about biotech acquisitions like everyone else. Instead, he says this group is the next fiery group to watch.
The "Fast Money" traders share their final trades of the day.
CNBC's Meg Tirrell reports on the action in the IBB biotech ETF after Pfizer announced it was buying Medivation and what some other big M&A deals could be coming down the line. The "Fast Money" traders weigh in.
Medivation surged more than 19 percent Monday after Pfizer said it would buy the cancer drug company for about $14 billion.
U.S. stocks closed mostly lower, with energy falling nearly 0.9 percent.
CNBC's Meg Tirrell reports the details on Pfizer's deal for Medivation.
CNBC's Meg Tirrell discusses the latest healthcare mergers and acquisitions.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
Boutique banks are taking more deal flow from the biggest firms on the Street.
Pfizer buys Medivation for $14 billion in cash. CNBC's Meg Tirrell reports the latest.
The acquisition will give Pfizer access to Medivation's successful cancer treatments under development.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Some of the names on the move ahead of the open.
Drugmaker Pfizer expects the deal to add $0.05 to EPS in the first year, reports CNBC's Meg Tirrell.
Pfizer is reportedly near a deal to acquire cancer drug company Medivation for approximately $14 billion, reports CNBC's Meg Tirrell.
Pfizer is in advanced talks to acquire Medivation for close to $14 billion, as it seeks to boost its oncology portfolio.